EUVIMEDEUVIMED entdecken
Open Access

Longitudinal monitoring of type 1 diabetes progression to disease onset

Jessica L King iD, Jyotirmoy Roy, Russell R Urie iD, Elizabeth Bealer iD, Kelly Crumley iD, Laila Rad iD, Scott A Soleimanpour iD, Lonnie D Shea iD

Science Advances · 2026

DOI: 10.1126/sciadv.adw8946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Jessica L King und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preventing autoimmune type 1 diabetes (T1D) necessitates improved monitoring for disease progression before symptom onset. Current diagnostic methods assess circulating autoantibodies, C-peptide levels, or dysglycemia, yet these approaches fail to identify β cell destruction preceding glucose dysregulation. Here, a subcutaneous microporous scaffold is used as an immunological niche (IN), which provides a nonvital accessible tissue reflecting many immune changes occurring in the pancreas. Sequencing analysis of the IN successfully delineates at-risk from nonrisk groups, as well as disease progressors from nonprogressors at 6 weeks of age in the nonobese diabetic mouse model. Within progressors, we identify disease 5 to 7 weeks before disease onset. Collectively, disease occurring in a poorly accessible site can be identified early by sampling a distant nonvital tissue, indicating the systemic nature of the disease and informing the timing of disease modifying therapies to halt or delay the progression of T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1AnimalsDisease ProgressionMiceAutoantibodiesHumansDisease Models, AnimalMice, Inbred NODFemaleInsulin-Secreting Cells

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
  • Division of Metabolism, Endocrinology and Diabetes and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
  • VA Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA.
  • Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.

ORCID-Profile: Jessica L King, Russell R Urie, Elizabeth Bealer, Kelly Crumley, Laila Rad, Scott A Soleimanpour, Lonnie D Shea

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • BLRD VA
  • National Institutes of Health
  • National Science Foundation Graduate Research Fellowship Program
  • Breakthrough T1D
  • U.S. Department of Veterans Affairs

Zitieren

APA

King, J. L., Roy, J., Urie, R. R., Bealer, E., Crumley, K., Rad, L., Soleimanpour, S. A., & Shea, L. D. (2026). Longitudinal monitoring of type 1 diabetes progression to disease onset. Science Advances. https://doi.org/10.1126/sciadv.adw8946

Vancouver

King JL, Roy J, Urie RR, Bealer E, Crumley K, Rad L, et al. Longitudinal monitoring of type 1 diabetes progression to disease onset. Science Advances. 2026. doi:10.1126/sciadv.adw8946

BibTeX
@article{King2026,
  author = {King, Jessica L and Roy, Jyotirmoy and Urie, Russell R and Bealer, Elizabeth and Crumley, Kelly and Rad, Laila and Soleimanpour, Scott A and Shea, Lonnie D},
  title = {Longitudinal monitoring of type 1 diabetes progression to disease onset},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.adw8946}
}
Kostenlos starten →